Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing breakthrough treatments for human disease. Lexicon has clinical-stage drug programs for diabetes and carcinoid syndrome in progress. The company was founded in 1995 and is based in The Woodlands, Texas.
LXRX Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Lexicon Pharmaceuticals Inc. To summarize, we found that Lexicon Pharmaceuticals Inc ranked in the 69th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 186.83% on a DCF basis. As for the metrics that stood out in our discounted cash flow analysis of Lexicon Pharmaceuticals Inc, consider:
38% of the company's capital comes from equity, which is greater than only 18.1% of stocks in our cash flow based forecasting set.
Lexicon Pharmaceuticals Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than merely 15.51% of tickers in our DCF set.
As a business, Lexicon Pharmaceuticals Inc experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than only 0% of stocks generating free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Lexicon Pharmaceuticals Inc? See ALXN, SGRY, FTLF, GTS, and PDEX.
Lexicon Pharmaceuticals (LXRX) commences patient dosing with blinded study drug in its RELIEF-DPN-1, a Phase 2 study of LX9211 for the treatment of diabetic peripheral neuropathic pain. The study is designed to enroll ~300 patients. The primary efficacy endpoint under evaluation is the change from baseline (Day 1) to Week 6...
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2020 Earnings Conference Call July 30, 2020 08:00 ET Company Participants Kimberly Lee - Head, Investor Relations and Corporate Strategy Lonnel Coats - President and Chief Executive Officer Alex Santini - Executive Vice President and Chief Commercial Officer Pablo Lapuerta - Executive Vice President and...